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Abstract
Adverse events upon smallpox vaccination with fully-replicative strains of Vaccinia virus (VACV) comprise an array of clinical
manifestations that occur primarily in immunocompromised patients leading to significant host morbidity/mortality. The
expansion of immune-suppressed populations and the possible release of Variola virus as a bioterrorist act have given rise
to concerns over vaccination complications should more widespread vaccination be reinitiated. Our goal was to evaluate
the components of the host immune system that are sufficient to prevent morbidity/mortality in a murine model of tail
scarification, which mimics immunological and clinical features of smallpox vaccination in humans. Infection of C57BL/6
wild-type mice led to a strictly localized infection, with complete viral clearance by day 28 p.i. On the other hand, infection
of T and B-cell deficient mice (Rag1
2/2) produced a severe disease, with uncontrolled viral replication at the inoculation site
and dissemination to internal organs. Infection of B-cell deficient animals (mMT) produced no mortality. However, viral
clearance in mMT animals was delayed compared to WT animals, with detectable viral titers in tail and internal organs late in
infection. Treatment of Rag1
2/2 with rabbit hyperimmune anti-vaccinia serum had a subtle effect on the morbidity/
mortality of this strain, but it was effective in reduce viral titers in ovaries. Finally, NUDE athymic mice showed a similar
outcome of infection as Rag1
2/2, and passive transfer of WT T cells to Rag1
2/2 animals proved fully effective in preventing
morbidity/mortality. These results strongly suggest that both T and B cells are important in the immune response to primary
VACV infection in mice, and that T-cells are required to control the infection at the inoculation site and providing help for B-
cells to produce antibodies, which help to prevent viral dissemination. These insights might prove helpful to better identify
individuals with higher risk of complications after infection with poxvirus.
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Introduction
The Vaccinia virus (VACV) is a member of Poxviridae family
and the Orthopoxvirus genus, which also includes several human
pathogens such as Variola virus (VARV), Cowpox virus (CPXV),
Monkeypox virus (MPXV), and the mouse-specific pathogen
Ectromelia virus (ECTV)[1]. The use of live, replicative VACV
was effective in providing protection against smallpox through
the elicitation of strong acute immune responses, followed by
viral replication control and induction of immune memory
[2]. However, in patients with immunodeficiency, virus
replication is poorly controlled and life threatening adverse
events have been reported [3]. Despite numerous recent
publications on vaccine-elicited immunity [4,5,6,7], little
progress has been made in understanding vaccination-related
adverse events. It is difficult to extrapolate this information
from current animal model studies, as most studies try to
model systemic orthopoxvirus disease in humans and there-
fore have used routes of administration that produce a
systemic infection in immunocompetent mice, such as
intranasal and intraperitoneal routes with high virus inocu-
lation [6,8]. Vaccination in humans however, is performed by
inoculating the virus via multiple skin punctures that produce
a localized infection, without systemic involvement in
immunocompetent patients (although traces of blood borne
viral DNA have been seen in a minority of patients in a few
studies), but can cause a wide range of complications in
immunocompromised individuals [9]. Tail scarification (ts)
infection in mice provides a useful model to study the
complications derived from VACV inoculation, since it
resembles the immunological and virological parameters of
human smallpox vaccination [10].
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generation of a Th1 response is important for the control of these
infections. Freyschmidt and colleagues reported that upon VACV
infection by tail scarification, Relb knockout mice (deficient in a
transcription factor belonging to the NF-kB family) have a more
severe disease than WT mice and that this higher susceptibility is
related to their inability to mount a normal Th1 response [11].
Additionally, in vivo overexpression of the Th1 cytokine IL-1a
(K14/IL-1 a) differentially modulates the immune response to
VACV, leading to a higher control of viral replication when
compared to wild type mice [12]. Furthermore, a recent study has
shown that upregulation of interleukin (IL) 17 in a mouse model of
atopic dermatitis decrease NK cell activity and led to a higher viral
replication at the skin [13]. Regarding human studies, Howell and
co-workers reported that human skin biopsies from patients with
atopic dermatitis (a Th2 inflammatory skin disease) have a
defective innate immune response to VACV [14]. However, due
to the diverse attributes of a ‘‘Th1 response’’, it is not known
exactly which facet of this response is crucial to prevent VACV
dissemination.
Among the main effectors elicited by the Th1 response, T and B
cells are the better studied. Their participation in the immune
response to a primary poxvirus infection has been well-
documented in several models of poxvirus infection. Upon
intraperitoneal VACV infection, a strong humoral immune
response is necessary to control the infection and CD8
+ T cell
response is needed only when the antibody response is abrogated
[15]. In the case of the mouse-specific pathogen ECTV infection,
both T and B cells are necessary to control the infection and to
avoid mortality [8,16]. The role of humoral immunity has been
revealed also by the prophylactic or therapeutic use of anti VACV
antibodies in mice [17].
Despite the generation of a significant amount of data focusing
on the understanding of primary VACV infection immunity by
many research groups, no definitive conclusions about which
component of the host immune system is crucial to an effective
immune response to poxvirus inoculations in human vaccinees
have yet been presented. While some authors pointed to T cells as
the main cell type responsible for viral clearance based on animal
studies and clinical trials [3,11], others believed instead that the
antibodies are essential to this process [18]. Hence, the objective of
the present study is to add some insights into the understanding of
the relative role of T cells, B cells and pro-inflammatory cytokines
in the response to a localized, primary poxvirus infection. Using an
array of knockout mice, we saw that the deletion of pro-
inflammatory cytokines (IL-12/23, TNFa or IFNc) or immune
mediators (iNOS) had no effect on the immune response to VACV
and that T and B cells are required for VACV clearance, with a
more important role played by T cells.
Results
Absence of single pro-inflammatory mediators does not
affect the outcome of infection
To test the role of inflammatory cytokines in this model,
animals deficient in IL-12/23 or TNF were infected with
VACV-WR by tail scarification. Like the wild type mice
(C57BL/6), these strains did not show any weight loss or signs
of disseminated disease (Figure 1A). Furthermore, IFNc and
iNOS deficient mice also did not show signs of disseminated
disease (Figure 1B). Nevertheless, IFNc
2/2 mice showed
different lesion development kinetics, with a delayed healing
starting at day 10 p.i. and continuing throughout the
experiment (until day 28 p.i.). At day 10 p.i., WT animals
developed a dry scab compared to a more purulent lesion in
IFN-c-deficient mice (Figure S1). iNOS
2/2 mice showed the
same lesion kinetics as WT mice (Figure S1), suggesting that
the phenotype in IFN-c-deficient mice was not related to lack of
induction of iNOS. In spite of that, viral titers in tails were
similar among WT, iNOS
2/2 and IFNc- d e f i c i e n tm i c ea td a y s
3 ,5a n d7p . i .( Figure 1C), suggesting-that these cytokines/
immune mediator have a lesser impact on the VACV infection
control in the presented model.
Mice lacking adaptive immunity had severe disease with
higher viral replication in organs
Mice lacking T and B cells (Rag1
2/2) were also inoculated with
VACV-WR by tail scarification. Unlike wild type and single
cytokine-deficient animals, Rag1
2/2 mice had a statistically
significant weight loss starting at the second week post-infection
(one-way ANOVA, p,0.01; Figure 2A) and 100% of them
reached the euthanasia end-point (log-rank test p,0.01, median
survival 17 days; Figure 2B). Moreover, beginning at the second
week of infection, all the Rag1
2/2 mice clearly showed clinical
signs of disseminated disease, such as ruffling fur, arched back and
disseminated poxvirus lesions, primarily on the face, forepaw and
tail (Figure 3A).
The lesions at the inoculation site showed quite different kinetics
in Rag1
2/2 mice when compared to WT mice. While in the latter
the lesion progressed from papules/pustules to a scab in the first 10
days of infection, in the former the lesion took longer to heal, with
no complete healing by day 15 p.i. (Figure 3B). This finding leads
us to evaluate the viral replication at this site. Indeed, viral
replication was higher at the initial site of infection in Rag1
2/2
mice (t test, p,0.01). Additionally, while WT mice presented a
strictly localized infection with no viral replication in evaluated
internal organs, Rag1
2/2 had an extensive replication in spleen
and ovaries at both analyzed time points (p,0.05, one sample t
test, Figure 2C).
Antibody response protects mice against viral
dissemination, but not from mortality
Analysis of the antibody response in wild type mice (C57BL/6)
showed that ELISA IGg titers were detectable starting at day 10
p.i. and increased until day 60 p.i., the last day analyzed
(Figure 4A). The appearance of IgG correlates well with the
time Rag1
2/2 animals started to lose weight (Figure 2A).
Hence, we evaluate if antibody treatment could prevent the
morbidity/mortality seen in Rag1
2/2 mice. Animals treated with
rabbit anti-vaccinia serum had a delayed mortality compared to
non-treated animals (Figure 4B), even though the difference
was not statistically significant. When the viral replication was
analyzed at days 10 and 15 p.i. in antibody-treated mice, viral
levels were similar in the tail (Figure 4C), but otherwise
statistically smaller in the ovaries of treated animals (Figure 4D)
(t test, p,0.05).
To test the role of antibodies with another approach, B cell-
deficient mice (mMT) were infected with VACV-WR and
followed as above. These animals did not show any weight loss
in the time analyzed (Figure 5A) and no mortality was observed
(Figure 5B). Unexpectedly, these mice had a delayed control of
viral replication at the initial site of infection, since they had
detectable viral particles in the tail by day 28 p.i., while WT
animals had completely cleared the infection (Figure 5C).
Furthermore, the animals deficient only in B cells had higher
titers on internal organs, such as the ovaries, than the WT mice,
but smaller than the B and T-cell deficient mice (Figure 5D). By
Host Control of Localized Vaccinia virus Infection
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(Figures 5C and 5D).
Animals deficient in T cells had a similar outcome of
infection as Rag
2/2 mice
As the antibody response seems not to be sufficient to control
morbidity/mortality in VACV primary infection, we sought to
evaluate the role of T cells in viral clearance. NUDE athymic
animals (nu/nu) or their wild type counterparts (nu/+) were infected
with VACV by tail scarification and followed as before. NUDE
mice (in opposition to their nu/+ littermates) showed similar
clinical signs of infection to Rag1
2/2 mice, including decreased
activities, disseminated lesions in the tail (data not shown) and
significant weight loss (p,0.001, unpaired t test, Figure 6A),
culminating with the death of all animals in the group (Mean
survival: 17 days, p,0.001 compared to nu/+ animals, Figure 6B).
Again, as in Rag1
2/2 mice, clinical signs of disease in nu/nu
animals correlate with a higher viral replication in the initial site of
infection (t test, p,0.05, Figure 6C) and in the spleen at days 10
and 15 p.i. (Figure 6D). Consistent with the role of T cells to
provide help to B cells, the ELISA IgG titer in sera of NUDE
animals was significantly reduced when compared to nu/+ animals
(unpaired t test, p,0.01 day 10 p.i. and p,0.001 day 15 p.i.,
Figure 6E).
Concomitant passive transfer of CD4
+ and CD8
+ T cells,
but not of these cells alone, fully protects mice against
morbidity and mortality caused by primary VACV
infection
To further investigate the role of T cells to protect animals of
generalized disease, Rag1
2/2 mice were passively transferred with
populations enriched in both CD4
+ and CD8
+ T cells, isolated
from spleens of WT mice. The purity of these enriched
populations was assured by flow cytometry (CD4+ T cells:
90.2% pure; CD8
+ T cells: 84.0% pure, Figure S3A). Animals
that received both T cell types showed a remarkable improvement
in their clinical signs, exhibiting no significant weight loss
(Figure 7A) nor other signs of systemic infection (data not
shown), similar to animals that passively received whole spleno-
cytes (Figure 7A). On the other hand, animals that received
CD4
+ or CD8
+ T cells alone showed clear weight loss and signs of
disease between days 10 and 15 p.i. (p,0.001, Figure 7A),
culminating with the death of 3 out of 6 animals (CD4
+ only
group) and 1 out of 6 (CD8
+ only group) (Figure 7B). The lesion
development kinetics of Rag1
2/2 mice reconstituted with WT T
cells was similar to that of mice reconstituted with whole
splenocytes, with the formation of a scab already by day 10 p.i.
On the other hand, animals that received just one T cell type
Figure 1. VACV infection in single-cytokine deficient mice did not alter the outcome of infection. C57BL/6 (n=6), IL-12/23
2/2 (n=4),
TNFR
2/2 mice (n=7), IFNc
2/2 (n=6) and iNOS
2/2 (n=6) animals were infected with 10
7 p.f.u. of VACV-WR by tail scarification. (A) Weight curve of
C57BL/6, IL-12/23
2/2, TNFR
2/2 mice. (B) Weight curve of IFNc
2/2 and iNOS
2/2 mice. (C) WT, IFNc
2/2 and iNOS
2/2 animals were euthanized at days
3, 5 and 7 post-infection (p.i.) and viral titers in tails were assessed by titration in BSC-40 cells. Bars represent the mean and standard error (SEM). The
results shown are representative of two separate experiments.
doi:10.1371/journal.pone.0018924.g001
Host Control of Localized Vaccinia virus Infection
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similar to non-treated animals (Figure S2). Despite the clinical
signs showed by mice that received only one cell type, viral titers in
the tail was diminished in these mice as well in mice that received
both T cells together, compared to non-treated Rag1
2/2 animals
(p,0.05 at day 10 p.i. and p,0.001 at day 15 p.i., Figure 7C).
Furthermore, viral titer in ovaries was also diminished in all
reconstituted mice, especially in mice reconstituted with WT T
cells together (p,0.001, Figure 7D). To confirm the functionality
of the transferred cells, flow cytometric analysis was performed
with splenocytes of reconstituted mice at days 10 and 15 p.i. This
analysis showed that the percentage of activated splenocytes
(producing IFN-c) is similar between mice that received both T
cell types compared to animals that received only one type
(Increase in the percentage of splenocytes producing IFN-c
between days 10 and 15. Mock infected: 1.28-fold increase;
CD8 plus CD4: 12.8-fold increase; CD8 only: 15.1-fold increase
and CD4 only: 14.66-fold increase, Figure S3B and C).
Discussion
The adverse events following smallpox vaccination includes a
variety of clinical manifestation, ranging from a limited viral
spread around the site of inoculation to more severe outcomes,
such as viral dissemination to internal organs [3,9]. At the time of
the Variola virus (VARV) WHO eradication campaign, these
complications were relatively rare, and considering that smallpox
was endemic or epidemic in these regions, smallpox immuniza-
tions were more beneficial than harmful [2]. However, with the
increase of the number of immunocompromised individuals
(immunosuppressive therapy, HIV/AIDS) seen today, the risk of
complications upon smallpox vaccination, with fully-replicative
VACV strains, is higher and may preclude widespread use in a
vaccination campaign, or use as a vector against several pathogens
[19]. Moreover, these immunodeficient patients are also more
susceptible to infections with other zoonotic poxviruses, such as
Monkeypox virus (MPXV) and Cowpox virus (CPXV) [20,21].
Nowadays, there is an ongoing debate about which components
of the host immune system are required and sufficient to control a
VACV primary infection, regardless if it is natural or by means of
vaccination. Some authors attribute the main role to T cells
[3,8,11] and others to B cells and antibodies [15,18]. Hence, our
objective was to better understand those adverse events upon
smallpox vaccination using the murine model of tail scarification.
Our results suggest that the infection in C57BL/6 WT mice is
strictly localized, since we were not able to detect virus in internal
organs (ovaries and spleen) of these mice in all times analyzed
(Figure 2C), and no signs of weight loss was observed
(Figure 1A and not shown), confirming other findings in the
literature [11,22]. Moreover, freshly isolated splenocytes from
Figure 2. T and B-cell deficient mice had severe disease upon tail scarification infection with VACV-WR. Rag1
2/2 animals (n=6) were
infected with 10
7 p.f.u. of VACV-WR by tail scarification. (A) Weight curve of infected or mock-infected Rag1
2/2 mice (**p,0.01, unpaired t test). (B)
Animals were followed during 60 days post-infection (p.i.) to compute mean survival (**p,0.01, log-rank test). (C) WT and Rag1
2/2 animals were
euthanized at the times indicated and the tail, spleen and ovaries were removed and titrated in BSC-40 cells. Bars represent the mean and standard
error (SEM). The results are representative of three experiments.
doi:10.1371/journal.pone.0018924.g002
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and 15 p.i., suggesting that the infection is cleared in the
inoculation site, with low systemic immune activation (data not
shown). Many cytokines are involved in VACV clearance in other
models of infection and studies in humans including IL-12 and
IL-23 [23,24], TNF-a [25] and IFN-c [26]. Furthermore, the
inducible nitric oxide synthase (iNOS) has been involved in the
response to VACV in vitro [27,28], but its role in vivo is uncertain
[29]. Thus, we sought to evaluate the role of these cytokines and
immune mediators in the VACV tail scarification model. IL12/
23p40, TNFRp55, IFNc and iNOS knockout animals did not
show any weight loss upon infection with VACV (Figure 1A).
Furthermore, despite the phenotypic difference in lesion kinetics,
viral replication was similar in tails of WT, IFNc KO and iNOS
KO (Figure S1 and 1C). These findings suggest that these
cytokines alone are not important for the control of primary
localized infection in mice. This could be explained by the
functional redundancy of cytokines, where a single cytokine can
be functionally replaced by others. For example, IL-18 is
functionally similar to IL-12 [30] and is also important in VACV
immune response [23]. The antiviral cytokine IL-15 is related to
IL-2 and has its role in the control of VACV infection [31].
Confirming the involvement of multiple cytokines in this model,
RelB (a transcription factor of the NF-kB family) knockout mice
are more susceptible to VACV infection by tail scarification due
to the lower IFN-c production allied to an increase of the Th2
cytokines IL-4, IL-5 and IL-10 [11].
Given that canonical Th1 cytokines seem not to be crucial alone
in the immune response to VACV, we sought to evaluate the role
of adaptive immunity in this context. Rag1
2/2 animals are T and
B cell deficient, due to the disruption of the recombination
activation gene 1, responsible for the somatic recombination that
occurred in T and B cells precursors upon maturation. Despite the
lack of T and B cells, they retain normal or even higher levels of
other bone marrow-derived cells, such as macrophages and
natural killers (NK cells) [32]. Infection of Rag1
2/2 mice led to
the development of a generalized disease, with disseminated
poxvirus lesions in the face, forepaw and tail, which culminate
with the mortality of 100% of the animals (Figure 3A). Moreover,
the lesions in Rag1
2/2 mice took longer to show signs of healing
when compared to WT controls and viral titers in tail of these mice
were 1 log higher when compared to WT control mice
(Figure 2C). Nevertheless, whilst WT mice had no detectable
viral titers in spleen and ovaries in all times analyzed, Rag
2/2
animals harbored an intensive viral replication in these organs
(Figure 2C). Altogether, these findings suggested that the host
adaptive immunity is essential to control the replication and
dissemination of VACV in the murine model of tail scarification.
Figure 3. Clinical signs and lesion kinetic in T and B-cell deficient mice. Rag1
2/2 animals (n=6) were infected with 10
7 p.f.u. of VACV-WR by
tail scarification. (A) Clinical signs of disseminated disease in Rag1
2/2. Starting on the second week post-infection, Rag1
2/2 mice had signs of
generalized disease, such as ruffled fur, arched back and disseminated lesions, primarily at the face, forepaw and tail. The animal shown is
representative of the group. (B) Rag1
2/2 presented a delayed lesion healing compared to WT mice. Note the ulcerative, purulent nature of the lesion
in Rag1
2/2 compared to the scab formed in C57BL/6 animals. Photos are representative of the groups indicated. Black bar represents 1 cm.
doi:10.1371/journal.pone.0018924.g003
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other studies of poxvirus infection in mice [6,8].
Even though the importance of adaptive immunity to control
poxvirus infections has been universally accepted, the relative
contribution of T and B cells in this process is still a matter of
debate [3,18]. Once the antibody response is essential in primary
and secondary poxvirus infections using generalized infection
models, such as intranasal and intraperitoneal [4,8,16,33], we
evaluated the role of B cells and antibodies in the present model.
WT animals infected with VACV by tail scarification mounted a
robust IgG antibody response. The time of appearance of long-
lived IgG antibodies correlates well with the appearance of clinical
signs in Rag1
2/2 mice (Figure 2 and 3), suggesting that
antibodies might be relevant in this model. To test this hypothesis,
Rag1
2/2 mice were infected with VACV-WR and passively
immunized with polyclonal rabbit anti-VACV serum. Treated
animals showed a slightly improvement in their mortality
compared to Rag1
2/2animals treated with rabbit naı ¨ve serum
(Figure 4B). Viral titers in tail are similar between antibody
treated and non-treated animals (Figure 4C), but the former had
lower virus titer in ovaries compared to non-treated animals
(Figure 4D), indicating that the antibody response seems to be
efficient in reduce viral dissemination to internal organs. To
further understand the role of antibodies in this model and to
circumvent issues associate with an interspecific serum transfer
[34], animals deficient in B-cells (mMT) were infected with VACV-
WR as described before. mMT mice did not show any sign of
generalized disease and did not die upon tail scarification infection
with VACV-WR (Figure 5A and 5B). These animals harbored
low levels of viral replication in ovaries at days 10, 15 and 28 p.i. It
corroborates the hypothesis that the antibodies might be
responsible for the control of viral dissemination. By day 60 p.i.,
all mMT animals have completely cleared the infection
(Figure 5D). This kind of persistent infection was also seen in
other viral infections in mMT animals [35]. Previous studies had
demonstrated the importance of the B cell response to the control
of poxvirus infection. Upon intraperitoneal infection with VACV-
WR, animals that are unable to mount a humoral response had
signs of severe disease with consequent death [15]. Previous studies
had demonstrated that infection of mMT mice with the exclusive
mouse pathogen Ectromelia virus (ECTV) led to virus persistence in
internal organs and host death late in infection [8,16]. The
difference between the outcomes seen in these studies and the one
presented here is likely due to different models of infections and
viruses used, respectively [36]. Moreover, PBMC from human
donors infected with wild strains of VACV showed a remarkable
down-modulation of monocytes, CD4
+ T cells and B cells (Gomes
et al., unpublished results), highlighting the importance of these cell
types in the immune response to VACV.
The next step was to evaluate the contribution of T cells to
VACV immunity using the T-cell deficient mice (NUDE athymic,
nu/nu) and their normal littermates (nu/+). The NUDE athymic
animals have a defect in thymus’ development and do not posses
mature T cells [37]. These animals had a very similar outcome of
infection as Rag1
2/2, with severe weight loss and 100% mortality
(Figure 6B). It is worth to mention that the median survival was
Figure 4. Antibody response seems not crucial to prevent mortality, but it is important to block viral dissemination. (A) WT (C57BL/6)
mice were infected with 10
7 p.f.u. of VACV-WR by tail scarification and euthanized as described. Sera were collected at the times indicated. Indirect
IgG ELISA was performed using purified VACV-WR as antigen (10
6 p.f.u./well). Bars represent mean and standard deviation (SD). ND: not detected. (B)
Survival curve of Rag1
2/2 animals inoculated with anti-VACV rabbit serum or rabbit naı ¨ve serum intraperitoneally every week after infection. At days
10 and 15 p.i., the tails (C) and the ovaries (D) were removed and titrated in BSC-40 cells. Bars represent mean and standard error (SEM). *p,0.05,
unpaired t test.
doi:10.1371/journal.pone.0018924.g004
Host Control of Localized Vaccinia virus Infection
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2/2 mice (17 days)
(Figure 2B and 6B). Viral titers were also significantly higher
in tails of NUDE mice compared to WT animals (Figure 6C).
Like C57BL/6 animals, normal nu/+ mice did not harbor viral
replication in internal organs at any time analyzed, contrasting
with NUDE animals, which had high viral titers in spleen
(Figure 6C). Another study showed that NUDE athymic mice
also succumb to a localized infection with VACV strain Lister,
reinforcing the role of T cells in the immune response to VACV
[38]. Despite the compelling evidence for the requirement of T
cells in the control of primary VACV presented here, we could not
rule out the role of the antibodies, once NUDE animals had
significantly lower IgG titers compared to nu/+ mice (Figure 6D).
This T helper-dependent production of antibodies is well known in
cases of poxvirus infection in humans [39] and in mice [15].
To further confirm the role of T cells in this model, Rag1
2/2
animals were passively transferred intravenously with C57BL/6
spleen-derived populations enriched in CD4
+ or CD8
+ T cells or
both cells in combination. Animals passively transferred with both
cell types were fully protected against morbidity (Figure 7A) and
mortality (Figure 7B), while animals that received only one cell
type respond poorly to infection, with a significant weight loss
between days 10 and 15 p.i. (Figure 7A). The survival curve of all
reconstituted animals were significant different from Rag1
2/2 non-
treated mice (**p,0.01, Figure 7B), but fully protection was
achieved only in the presence of both cell types. Control animals
that received WT whole splenocytes did not show any signs of
generalized disease (Figure 7A and data not shown). All animals
that were passively transferred showed a remarkable reduction in
viral replication in tail and ovaries, and this reduction was more
pronounced in animals that received both T cells (Figure 7C). In
agreement, lesion healing was similar between Rag1
2/2 reconsti-
tuted with WT T cells or WT whole splenocytes, and it was
deficient in animals that received only one T cell subtype (Figure
S2). The morbidity/mortality observed in animals reconstituted
with CD4
+ or CD8
+ T cells alone was not due to a functional
defect of these cells, since freshly isolated splenocytes of these mice
showed a similar percentage of IFN-c positive cells compared to
the WT T cells reconstituted group (Figure S3B and S3C). The
groups that received either T cell types or only one cell type did
not show any neutralizing activity in serum, indicating that the cell
population inoculated did not contain B cells, which would affect
the result obtained. These findings strongly suggested that both
CD4
+ and CD8
+ T cells are required to prevent morbidity/
mortality upon primary VACV infection. The role played by host
T cells in VACV localized infection seems to be the control of viral
replication at the initial site, once Rag1
2/2 had higher titers and
delayed healing in the tail when compared to WT mice
(Figure 2C and 3B) and the passive transfer of WT cells to
Rag1
2/2 mice decrease viral replication at this site and led to
complete healing, similar to animals reconstituted with whole
splenocytes (Figure 7C and S2).
Figure 5. B-cell deficient mice did not show any signs of disseminated disease, but had delayed viral clearance. mMT mice (n=6) were
infected with 10
7 p.f.u. of VACV-WR by tail scarification. (A) Weight curve of mMT mice infected with VACV-WR or mock-infected. (B) The same animals
were followed for 60 days to compute mean survival. (C) Viral titers were determined in tails of C57BL/6 and mMT mice at days 10, 15, 28 and 60 p.i.
(*p,0.05 and **p,0.01, t test). (D) Viral titers were determined in ovaries of mMT mice at days 10, 15, 28 and 60 p.i. and of Rag1
2/2 mice at days 10
and 15 p.i.(*p,0.05 and **p,0.01, t test). Bars represent mean and standard error (SEM). Results shown are representative of two experiments.
doi:10.1371/journal.pone.0018924.g005
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shown the relevance of T cells to the primary immune response to
poxviruses [8,11], as well as in secondary responses [25]. Our
results also showed that reconstitution of Rag1
2/2 mice with CD8
+
T cells proved more efficient than reconstitution with CD4
+ T cells
alone (Figure 7). Recently, Xu and coworkers reported that direct
antigen presentation to CD8
+ T cells is sufficient to prime an
efficient anti-viral cytotoxic response [40], which would enable
these cells to fully activate upon VACV infection in the absence of
T cell helper. Another study by Spriggs and co-workers, however,
reported that b2-microglobulin deficient mice, which do not have
mature CD4
-CD8
+ T cells, did not show any signs of generalized
disease when inoculated with the same dose of VACV-WR by tail
scarification [22]. This discrepancy between the results could be
due to the different strategies employed. While Spriggs’ group used
a transgenic knockout mice, we used a passive transfer strategy in a
severely immunocompromised mice (Rag1
2/2). It has been
demonstrated that, in the absence of B cell/antibody response
(as in our strategy), CD8
+ T cells can protect mice from an
otherwise lethal infection with VACV [6,15]. The role of CD8
+ T
cells in this model deserves future detailed studies.
As far as we concern, this is the first study to use a systematic
approach to access immunity to VACV using the tail scarification
model in mice, which more close resembles the vaccination by skin
punctures in humans [10]. Taken together, our results strongly
suggest that both T and B cells are required to VACV clearance in
mice. Based on the findings presented, we hypothesize the
following scenario: upon VACV infection by tail scarification, T
cells are recruited to the initial site where they control viral
replication (Figure 2C and 6C). The activation and attraction of
T cells to the site of infection is important not only for the control
of viral replication (Figures 2 and 6), but also for the priming of
B cells with the consequent production of anti-VACV antibodies
[33,39](Figure 6D). The anti-VACV antibodies are then
important to control viral dissemination to internal organs in the
late time of infection (Figures 4D and 5D). The complete
understand of the immune mechanisms responsible for protection
of a primary poxvirus infection is of major interest due to the
serious adverse events post smallpox vaccination. This knowledge
will enable us to better identify individuals with higher risk of
complications after vaccination or natural infection with poxvirus,
design more efficient poxvirus-based vaccines that specific
stimulate the T cell response and design therapeutic strategies
for treatment of poxvirus infections in humans.
Materials and Methods
Ethics Statement
All experimental protocols were carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Ethics Committee for Animal
Experimentation (CETEA/UFMG, Brazil, protocol #110/2008)
and the CDC Institutional Animal Care and Use Committee
Figure 6. Mice lacking T cells are as susceptible to primary VACV infection as Rag1
2/2 mice. NUDE athymic mice (nu/nu) and their wild
type littermates (nu/+) were infected with 10
7 p.f.u. of VACV-WR by tail scarification. (A) Weight curve of NUDE mice (***p,0.001, unpaired t test). (B)
Survival curve of nu/nu and nu/+ after infection (***p,0.001, log-rank test). (C) Viral titers were determined in tail of C57BL/6 and nu/nu mice
(**p,0.01 day 10 p.i. and *p,0.05, t test). Data of viral titer in tails of nu/+ mice are missing. (D) Spleens of nu/nu and nu/+ mice were removed at the
times indicated and virus titer was determined in BSC-40 cells. (E) VACV-specific IgG antibodies were determined by ELISA in serum of nu/nu and nu/+
mice (**p,0.01 and ***p,0.001, t test). Bars represent the mean and standard error (SEM), except for 6E, where bars represent mean and standard
deviation (SD). The results shown are representative of two experiments. ND: not detected.
doi:10.1371/journal.pone.0018924.g006
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showed any signs of pain and distress were treated with the
analgesic buprenorphine (0.05–0.1 mg/kg) given subcutaneously
every 8–12 hours in an effort to minimize suffering.
Virus and Cells
Cercopithecus aethiops epithelial kidney cells (BSC-40, ATCC
number CRL-2761) were maintained in RPMI 1640 medium
(Gibco, USA) supplemented with 10% fetal calf serum (FCS,
Gibco, USA) and penicillin (200 U/ml), gentamicin (50 mg/ml)
and fungizone (2.5 mg/ml). The VACV strain Western Reserve
(WR, ATCC number VR-1354) was propagated in BSC-40 cells
and purified using ultracentrifugation in sucrose gradient.
Mice and Infection
C57BL/6 mice were provided by CEBIO/UFMG, Brazil.
Rag1
2/2 and IFNc
2/2 animals were provided by Rene ´
Rachou Institute (FIOCRUZ, Brazil). IL-12/23 knockout
(IL12/23p40
2/2) ,t u m o rn e c r o s i sf a c t o rr e c e p t o rk n o c k o u t
(TNFrp55
2/2) and NUDE athymic mice (nu/nu)a n dt h e i rw i l d
type counterpart (nu/+) were provided by the Biochemistry and
Immunology Department/UFMG, Brazil. IL-12/23p40
2/2
Figure 7. Rag1
2/2 mice passively transferred with both T cells were fully protected from VACV infection. Spleens of naı ¨ve C57BL/6 mice
were removed and made into single-cell suspension and this population was enriched in CD4
+ and CD8
+ T cells using a negative selection system. (A)
Rag1
2/2 were inoculated intravenously with either CD4
+ and CD8
+ T cells or either type alone (n=6 per group). As a control, Rag1
2/2 mice received
splenocytes prior to isolation intravenously (10
7 viable cells). Four days after inoculation, all animals were infected with VACV-WR by tail scarification
and weighted daily (***p,0.001, paired t test). Bars represent mean and SEM. (B) Survival curve of Rag1
2/2 passively transferred with both CD4
+ and
CD8
+ T cells or with either type alone, compared to the mortality in the same strain without previous treatment (**p,0.01, log-rank test). Viral titers in
tail (C) and ovaries (D) of mice passively transferred with WT T cells and infected with VACV-WR. Bars represent mean and standard error (SEM)
(*p,0.05, **p,0.01 and ***p,0.001 compared to Rag1
2/2 non-treated group, t test). The results shown are representative of two experiments (CD4
+
plus CD8
+ T cells group). For animals that received only CD4
+ or CD8
+ T cells, only one experiment was performed.
doi:10.1371/journal.pone.0018924.g007
Host Control of Localized Vaccinia virus Infection
PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18924matrices were a kind gift from Dr. Luiz Vicente Rizzo
( U n i v e r s i d a d ed eS a ˜o Paulo, Sa ˜o Paulo, SP, Brazil),
TNFrp55
2/2 were purchased from Jackson Laboratory
(B6.129-Tnfrsf1a
tm1Mak/J, Bar Harbor, MN, USA). Addition-
ally, C57BL/6 (C57BL/6J), Rag1
2/2 (B6.129S7-Rag1tm1-
Mom/J), IFNc
2/2 (B6.129S7-Ifngtm1Ts/J), iNOS
2/2 (B6.
129P2-Nos2tm1Lau/J) and mMT (B6.129S2-Igh-6tm1Cgn/J)
mice were purchased from the Jackson Laboratory. Food and
water were provided ad libitum and the animals were used
between 8 and 12 weeks of age. Animals were anesthetized with
an intraperitoneal injection of Ketamine (100 mg/Kg of body
weight) and Xylazine (10 mg/Kg) diluted in sterile phosphate
buffered saline (PBS). Thirty scarifications were made with a
26 G syringe in 1 cm along the base of the tail avoiding
bleeding, as previously described [10]. After that, 10 mlo fP B S
containing 10
7 plaque forming units (p.f.u.) of VACV-WR were
added to the area and allow to air dry. Only PBS was added in
the mock-infected animals. All animals were daily weighted and
checked for signals of disseminated disease (such as ruffling fur,
arched back, and decreasing activities). Any animal that
presented more than 25% of weight loss was humanely
euthanized by cardiac puncture followed by cervical disloca-
tion, both performed under deep anesthesia.
Viral Titration in Organs
At different times post-infection, animals were humanely
euthanized as described above and tail, spleen and ovaries were
aseptically removed, weighted, and stored at 280uC until use. The
samples were homogenized in 1 ml of PBS using a 2000Geno/
Grinder (SPEX CertiPrep, USA). The homogenates were
sonicated for three minutes at 40% amplitude, freeze and thawed
twice (280u/37uC), sonicated again with the same conditions and
then serially diluted in RPMI 2% fetal calf serum (FCS). The
dilutions were added to monolayers of BSC-40 cells seeded in 6-
well plates, incubated for one hour at 37uC and 5% CO2
atmosphere and then 2 ml of the medium were added to each well
and further incubated at the same conditions for 48 hours. After
that time, cells were stained with a crystal violet solution (0.5%
crystal violet, 10% ethanol and 1% paraformaldehyde) for 20
minutes, washed again and the viral plaques were counted. The
number of plaques was multiplied by the reciprocal of sample
dilution and converted to p.f.u./g.
ELISA
Purified aliquots of VACV-WR were diluted in PBS and 10
6
p.f.u. were added per well in a 96-well plate (NUNC
Immunolon Maxisorb). The plates were incubated overnight
at 4uC, washed three times with PBS containing 0.05% Tween-
20 (PBS-T) and then blocked for two hours at 37uCw i t h
250 mL of PBS-T containing 1% bovine serum albumin (BSA).
The plates were washed again and then 100 mLo ft h es e r u m
serially diluted in a 1:2 ratio in PBS-T 0.5% BSA were added
per well. After 90 minutes at 37uC, the plates were washed
again and 100 mL of horseradish peroxidase-conjugate anti
mouse-IgG (KPL, Maryland, USA) diluted 1:1.000 in PBS-T
w e r ea d d e dp e rw e l la n di n c u b a t e da t3 7 uC for 60 minutes.
Following this, the plates were washed five times with PBS-T
and the substrate (citrate buffer 0.1 M pH 5.0, containing
0.3 mg/ml of ortho-phenylenediamine (OPD) and 0.03%
hydrogen peroxide) was added and incubated in dark for 5 to
15 minutes. The reaction was stopped by addition of 40 mlp e r
well of sulfuric acid 2N and the optical densities were measured
at 492 nm (Stat Fax 2100 Microplate Reader, Awareness
Technology, USA). The VACV specific IgG titer was given as
the highest serum dilution that exhibited an absorbance above
the median plus two standard deviations of five mock-infected
animals, as previously described [41,42].
Plaque Neutralization Reduction Test (PRNT)
Sera samples were heat-inactivated at 56uC for 30 minutes,
serially diluted in a 1:2 ratio in RPMI 1640 with 2% FCS and
incubated at 37uC for one hour with the same volume of RPMI
2%FCS containing 10
3 p.f.u./ml of VACV-WR. At the same
time, the viral suspension was also incubated with a 1:20 dilution
of FCS in RPMI to serve as a virus control. After that, 400 mlo f
this mixture was added to BSC-40 cells seeded in 6-wells plates,
incubated for one hour at 37uC and 5% CO2 atmosphere and
then 2 ml of the medium were added to each well and further
incubated at the same conditions for 48 hours. The cells were then
stained with a solution of crystal violet for 20 minutes and the viral
plaques were counted. The results are expressed as the highest
serum dilution that was able to neutralize at least 50% of viral
plaques (PRNT50).
Passive transfer of anti-vaccinia serum and naı ¨ve T cells
For immune serum transfer experiments, 500 ml of anti-vaccinia
rabbit serum (PRNT50 titer: 8,000 neutralizing units per ml) was
administered intraperitoneally at day 6 p.i. and 250 ml was
intraperitoneally administered weekly thereafter. For control
groups, the same regimen was applied using naı ¨ve rabbit serum.
For passive transfer of T cells, spleens of naı ¨ve C57BL/6 mice
were aseptically removed and made into single-cell suspensions.
Following osmotic lysis of red blood cells with 1X RBC Lysis
Buffer (eBioscence, USA), splenocytes were washed and the
population was enriched in CD4
+ and CD8
+ T cells using the
DynalH Mouse CD4 Negative Isolation Kit and DynalH Mouse
CD8 Negative Isolation Kit respectively (Invitrogen Dynal AS,
Oslo, Norway), according to manufacturer’s instruction. These kits
are based on negative selection that produces antibody and
magnetic beads-free cells for posterior use. Viable cells were
identified by exclusion of 0.4% Trypan Blue (Gibco, USA),
washed twice in PBS and injected into the tail vein of Rag1
2/2
mice. The first group received 5610
5 CD4+ T cells and 5610
5
CD8+ T cells, the second only 10
6 CD4+ T cells and the third
only 10
6 CD8+ T cells. The isolation purity was confirmed by flow
cytometry. As a positive control, Rag1
2/2 mice were reconstituted
with 10
7 total splenocytes from naı ¨ve C57BL/6 mice prepared as
describe above. Four days after inoculation, these animals were
infected as described earlier.
Flow Cytometry
For flow cytometry, spleens of mice were pooled, made into
single-cell suspensions, counted and the viability analysis with
Trypan Blue was performed. After that, 10
6 splenocytes were
incubated with Mouse BD Fc Block (BD Pharmingen, USA) for 10
minutes on ice. The cells were then stained for cell surface
molecules, fixed, permeabilized, and stained for intracellular
molecules using the Cytofix/Cytoperm kit (BD Biosciences,
USA) according to the manufacturer’s instructions. The antibodies
used were PE-Hamster Anti-Mouse CD3e (clone 145-2C11) (BD
Pharmingen, USA), PerCP-Rat Anti-Mouse CD8a (clone 53-6.7)
(BD Pharmingen, USA), APC- Rat Anti-Mouse CD4 (clone RM4-
5) (Invitrogen, USA), FITC-Rat Anti-Mouse IFN-c (clone
XMG1.2) (Invitrogen, USA), besides the appropriate isotypes
controls. One hundred thousand events were captured with
FACSCalibur machine and the results analyzed using the FlowJo
software.
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Viral titers, ELISA IgG titers and weight curves were compared
using Student t test or one-way ANOVA test. Survival curves were
compared with log-rank test. All statistical analyses were
performed using the GraphPad Prism 4 software (La Jolla, CA,
USA).
Supporting Information
Figure S1 IFNc deficient animals had slightly different
lesion kinetic compared to WT mice. C57BL/6 animals and
IFNc and iNOS deficient animals were anesthetized and infected
with 10
7 p.f.u. of VACV-WR by tail scarification and the site of
inoculation photographed at days 0, 5, 10 and 15 post-infection.
IFNc deficient animals presented a more purulent lesion with poor
healing throughout the experiment. This phenotype is not
associated with the lack of induction of iNOS, once iNOS
deficient animals showed the same lesion kinetic as C57BL/6
mice. Animals mock-infected displayed the same macroscopic
appearance at the site regardless the strain analyzed. In this figure,
only WT mock-infected animals are shown. All the photos shown
are representative of the group.
(TIF)
Figure S2 Lesion kinetic in Rag1
2/2 animals passively
transferred with WT T cells. Rag1
2/2 mice were passively
transferred with 5610
5 CD4
+ plus 5610
5 CD8
+ T cells (WT T
cells), or 10
6 CD4
+ T cells or 10
6 CD8
+ T cells from WT (C57BL/
6) mice. All animals were infected four days later and followed
until day 60 p.i. As a control, Rag1
2/2 received also 10
7
splenocytes of C57BL/6 (splenocytes). The inoculation site was
photographed at days 0, 5, 10 and 15 p.i. The photos shown are
representative of the group. The lesion kinetic in Rag1
2/2 mice is
shown to comparison purposes.
(TIF)
Figure S3 Functionality of splenocytes after passive
transfer of WT T cells to Rag1
2/2 mice. (A) Flow cytometric
analysis of the T cell-enriched population (CD3
+CD4
+ to the left
and CD3
+CD8
+ to the right) derived from spleens of C57Bl/6
mice. Numbers shown are percentage of total cells expressing both
markers. (B) Rag1
2/2 mice were passively transferred with
different combination of T cells from WT (C57Bl/6) mice. At
days 10 and 15 p.i., spleens of these mice were pooled, made into
single-cell suspension and stained for intracellular IFN-c. Data are
shown as histograms. Gray-filled histograms represent isotype
controls. (C) The percentage of IFN-c
+ splenocytes in the different
groups is shown graphically.
(TIF)
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